Malignant tumors are important killers that lead to human death. According to data from the 2009 China Health Statistics Yearbook, more than 2 million people die from tumors every year in China. For example, lung cancer has the largest number of patients among all tumors, with a mortality rate of 30.83 per 100,000 people. In the current treatment of lung cancer, the effectiveness of drugs in treating patients is less than 70%, and 20%-40% of patients may have received wrong drug treatment. The resulting poor therapeutic efficacy, increased cost, delayed treatment time and toxic side effects cause huge economic and social losses. The development of individualized drug regimens through the detection of patients’ genes and biomolecular targets can have a significant effect on improving efficacy and economic efficiency. From theory to technology, from clinic to market, all show the infinite vitality of molecular diagnostic technology in individualized medicine. The era of molecular diagnostics in individualized medicine has arrived, and in the face of the far-reaching impact and great need of individualized therapy on the development of new drugs and clinical therapeutics, the development of molecular detection technology for individualized therapy in China and the research of its products should be highly valued and supported. This project will correlate the detection results of tumor-related molecules with the efficacy and toxic side effects of clinical drugs, establish a number of tumor molecular targets related to the efficacy and toxic side effects of drugs such as lung cancer, and set up the detection technology supporting the individualization of medication. These molecular targets and detection technologies will be used to guide clinical drug use, track the efficacy, toxicity and survival of patients, and verify their feasibility.